Bayer's $7.25 Billion Legal Hedge Precedes Supreme Court Showdown

Bayer stock holds gains as a $7.25B glyphosate settlement advances, but a pivotal Supreme Court hearing on April 27, 2026, could reshape its massive legal liability.

Bayer shares are holding firm above €40, defending a near-doubling of their value over the past year. This renewed investor confidence faces its most critical test yet in a fortnight packed with legal and corporate milestones, all pivoting on a single Supreme Court hearing.

The German conglomerate’s stock traded above €41 in Xetra dealings, buoyed by a combination of operational resilience and significant movement on its legal front. A Missouri court has granted preliminary approval to a massive $7.25 billion settlement package related to glyphosate litigation. Claimants in that state have until June 4 to opt into this deal or pursue their cases individually.

The $11 Billion Legacy and a Pivotal Hearing

This settlement is part of a staggering financial burden stemming from the Monsanto acquisition. Since 2018, Bayer has spent over $11 billion on litigation. The weight of these legal costs is pressuring cash flows; the company anticipates a negative free cash flow for 2026, with roughly €5 billion in payouts expected this year.

All eyes, however, are fixed on Washington. On April 27, 2026, Bayer will present oral arguments before the U.S. Supreme Court. The core issue is legal "preemption." The company contends that the federal pesticide law, FIFRA, overrides state-level warning requirements for its Roundup herbicide—a position supported by a past presidential administration. If the high court agrees, it could invalidate the legal basis for tens of thousands of pending lawsuits alleging links to non-Hodgkin's lymphoma. General attorneys from 18 states, including Texas and Florida, have filed briefs opposing this federal preemption, creating the split in lower courts that prompted the Supreme Court to take the case.

Operational Strength Amid Financial Strain

While managing this legal overhang, Bayer's core business is demonstrating notable strength, particularly in pharmaceuticals. The division is successfully offsetting revenue declines from older drugs like Xarelto and Eylea facing patent expiries. Newer blockbusters are driving growth: the prostate cancer drug Nubeqa and the heart and kidney treatment Kerendia are posting robust sales increases. Kerendia alone saw currency-adjusted revenue surge 88% last year.

This operational performance is providing crucial financial support. Bayer's net financial debt recently declined by 8.5% to approximately €29.8 billion. The company maintains its full-year guidance, targeting an adjusted EBITDA between €9.6 and €10.1 billion for 2026. Analysts currently peg earnings per share at €4.29 for the year. Notably, US import tariffs on pharmaceuticals have not forced a change to the annual outlook, as a trade agreement caps levies on European medicines at 15%.

A Fortnight of Defining Events

The coming weeks will be decisive. The sequence of events begins with the virtual Annual General Meeting on April 24, where shareholders will vote on an unchanged dividend of €0.11 per share. Following the Supreme Court hearing on April 27, the dividend will be paid on April 29.

Market observers are adjusting their views in light of these developments. UBS recently reaffirmed its Buy rating with a €52 price target. DZ Bank upgraded its stance from Sell to Hold, raising its fair value estimate to €44.

The first-quarter earnings report on May 12 will offer the next snapshot of operational health. Leadership of the key US pharmaceuticals business will also change hands, with Nelson Ambrogio taking the helm on May 1 to accelerate momentum.

The Supreme Court's ruling, expected by the end of its session in June, holds the key to Bayer's long-term valuation. A favorable decision for the company would remove the largest obstacle to a sustained share price recovery, potentially rendering thousands of future claims legally groundless. For now, investors are watching as Bayer navigates this intense period of legal reckoning and financial discipline.